JP2023022328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023022328A5 JP2023022328A5 JP2022197804A JP2022197804A JP2023022328A5 JP 2023022328 A5 JP2023022328 A5 JP 2023022328A5 JP 2022197804 A JP2022197804 A JP 2022197804A JP 2022197804 A JP2022197804 A JP 2022197804A JP 2023022328 A5 JP2023022328 A5 JP 2023022328A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 170
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 2
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 238000011374 additional therapy Methods 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 2
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 239000012624 DNA alkylating agent Substances 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 239000012661 PARP inhibitor Substances 0.000 claims 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024108689A JP7803577B2 (ja) | 2016-12-23 | 2024-07-05 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
| JP2025282012A JP2026049000A (ja) | 2016-12-23 | 2025-12-25 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438943P | 2016-12-23 | 2016-12-23 | |
| US62/438,943 | 2016-12-23 | ||
| JP2019533624A JP7264482B2 (ja) | 2016-12-23 | 2017-12-22 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
| PCT/US2017/068098 WO2018119351A1 (en) | 2016-12-23 | 2017-12-22 | Anti-sez6l2 antibodies and antibody drug conjugates |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533624A Division JP7264482B2 (ja) | 2016-12-23 | 2017-12-22 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108689A Division JP7803577B2 (ja) | 2016-12-23 | 2024-07-05 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023022328A JP2023022328A (ja) | 2023-02-14 |
| JP2023022328A5 true JP2023022328A5 (https=) | 2023-08-16 |
| JP7522477B2 JP7522477B2 (ja) | 2024-07-25 |
Family
ID=62627759
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533624A Active JP7264482B2 (ja) | 2016-12-23 | 2017-12-22 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
| JP2022197804A Active JP7522477B2 (ja) | 2016-12-23 | 2022-12-12 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
| JP2024108689A Active JP7803577B2 (ja) | 2016-12-23 | 2024-07-05 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
| JP2025282012A Pending JP2026049000A (ja) | 2016-12-23 | 2025-12-25 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533624A Active JP7264482B2 (ja) | 2016-12-23 | 2017-12-22 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108689A Active JP7803577B2 (ja) | 2016-12-23 | 2024-07-05 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
| JP2025282012A Pending JP2026049000A (ja) | 2016-12-23 | 2025-12-25 | 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11634486B2 (https=) |
| EP (1) | EP3559043A4 (https=) |
| JP (4) | JP7264482B2 (https=) |
| CN (2) | CN118271442A (https=) |
| CA (1) | CA3048224A1 (https=) |
| WO (1) | WO2018119351A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865415C (en) | 2012-02-24 | 2022-06-21 | Stem Centrx, Inc. | Anti sez6 antibodies and methods of use |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| PH12021552002A1 (en) | 2019-02-20 | 2022-09-19 | Denali Therapeutics Inc | Anti-trem2 antibodies and methods of use thereof |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| PE20221465A1 (es) | 2020-01-13 | 2022-09-21 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CN111620944B (zh) * | 2020-06-01 | 2023-03-21 | 长春师范大学 | 一种全人源化抗乙肝病毒单克隆抗体、制备方法及其应用 |
| WO2021252804A1 (en) * | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| US20250154287A1 (en) * | 2023-11-10 | 2025-05-15 | Pfizer Inc. | ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF |
| WO2025167503A1 (en) * | 2024-02-05 | 2025-08-14 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-sez6/b7h3 antibodies and uses thereof |
| CN121628915A (zh) * | 2024-08-29 | 2026-03-10 | 上海泰槿生物技术有限公司 | 产生限制的免疫球蛋白轻链库的细胞、动物和方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6365154B1 (en) * | 1998-09-28 | 2002-04-02 | Smithkline Beecham Corporation | Tie2 agonist antibodies |
| CA2611728A1 (en) | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| EP2263083A1 (en) | 2008-04-03 | 2010-12-22 | Novo Nordisk A/S | Dner-mediated cell purification of pancreatic endocrine pre-progenitor cells and their progeny |
| CA2865415C (en) * | 2012-02-24 | 2022-06-21 | Stem Centrx, Inc. | Anti sez6 antibodies and methods of use |
| EP2669682B1 (en) | 2012-05-31 | 2017-04-19 | Heinrich-Heine-Universität Düsseldorf | Novel prognostic and predictive biomarkers (tumor markers) for human breast cancer |
| US20140283157A1 (en) * | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| CN105209076A (zh) | 2013-03-15 | 2015-12-30 | 阿布维公司 | 抗体药物偶联物(adc)纯化 |
| AU2014312215B2 (en) | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| AU2014312310A1 (en) | 2013-08-28 | 2016-04-07 | Abbvie Stemcentrx Llc | Novel SEZ6 modulators and methods of use |
| MX391141B (es) * | 2014-08-07 | 2025-03-21 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-ceramida. |
| EP3034620A1 (en) | 2014-12-17 | 2016-06-22 | Diaxonhit | Compositions and methods for diagnosing thyroid cancer |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| TW202523682A (zh) | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| JP6621195B2 (ja) | 2015-07-17 | 2019-12-18 | 国立大学法人京都大学 | 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 |
-
2017
- 2017-12-22 CN CN202410333522.7A patent/CN118271442A/zh active Pending
- 2017-12-22 US US16/471,246 patent/US11634486B2/en active Active
- 2017-12-22 CN CN201780079974.5A patent/CN110121507B/zh active Active
- 2017-12-22 EP EP17882852.1A patent/EP3559043A4/en active Pending
- 2017-12-22 CA CA3048224A patent/CA3048224A1/en active Pending
- 2017-12-22 WO PCT/US2017/068098 patent/WO2018119351A1/en not_active Ceased
- 2017-12-22 JP JP2019533624A patent/JP7264482B2/ja active Active
-
2022
- 2022-12-12 JP JP2022197804A patent/JP7522477B2/ja active Active
-
2023
- 2023-03-28 US US18/191,722 patent/US20230331839A1/en active Pending
-
2024
- 2024-07-05 JP JP2024108689A patent/JP7803577B2/ja active Active
-
2025
- 2025-12-25 JP JP2025282012A patent/JP2026049000A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023022328A5 (https=) | ||
| JP2022101693A5 (https=) | ||
| RU2483080C2 (ru) | Антитела и иммуноконъюгаты и их применение | |
| JP5925875B2 (ja) | 抗体−薬剤コンジュゲート | |
| JP2020502271A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2020526584A5 (https=) | ||
| RU2020124944A (ru) | Антитела против egfr и конъюгаты антитело-лекарственное средство | |
| JP2020525542A5 (https=) | ||
| JP2018127469A5 (https=) | ||
| US11230610B2 (en) | Bivalent antibodies masked by coiled coils | |
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| FI3218005T3 (fi) | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä | |
| JP2019535731A5 (https=) | ||
| JP2017522871A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| JP2017510559A5 (https=) | ||
| SI2582728T1 (en) | Human Antibodies Conjugates against a Tissue Factor | |
| JP2014520088A5 (https=) | ||
| JP2020527332A5 (https=) | ||
| JP2014513717A5 (https=) | ||
| JP2016538318A5 (https=) | ||
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| IL308504A (en) | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
| CN110575548A (zh) | 靶向于cd73的抗体-药物偶联物及其制法和用途 |